@conference{f25b0b50fc6b495cbe62411338e1ceca,
title = "A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).",
author = "Lorch, \{Jochen H.\} and Tishler, \{Roy B.\} and Chau, \{Nicole Grace\} and Hanna, \{Glenn J.\} and Guilherme Rabinowits and Schoenfeld, \{Jonathan Daniel\} and Margalit, \{Danielle Nina\} and O'Neill, \{Anne M.\} and Donald Annino and Goguen, \{Laura A\} and Ravi Uppaluri and Harris, \{Ethan James\} and Alec Kacew and Julian Huang and Laura Ma and Patricia Mchugh and Haddad, \{Robert I.\}",
note = "6071 Background: Prognosis in smokers with LASCCHN remains poor. Activating mutations of PI3K are linked to poor outcome and PI3K activation in response to RT is implicated in resistance to CRT. Methods: In this phase I study, the oral pan-PI3K inhibitor B combined with CRT was tested in pts with stage III/IV LASCCHN and ≥10 pack-year history of tobacco use treated with curative intent.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2018",
month = may,
day = "20",
doi = "10.1200/JCO.2018.36.15\_SUPPL.6071",
language = "American English",
}